Introduction {#s1}
============

Behcet\'s disease (BD) is considered to be a long-term, complex inflammatory disorder which is characterized by vasculitis involving multiple organs [@pone.0098373-Sakane1]. The clinical traits for BD comprise relapsing ulcerations in the oral cavity and genitals, erythema nodosum, ulcer of the colon and recurrent iritis [@pone.0098373-Bang1], [@pone.0098373-Alpsoy1], [@pone.0098373-Alpsoy2]. Previous reports suggest that T cells play an important role in the pathogenesis of BD and an increased number of T cells is related with disease activity [@pone.0098373-Bank1]. It has been shown that both Th1 and Th17 cells are crucial to the development of BD [@pone.0098373-Kulaber1], [@pone.0098373-Chi1].

Vogt--Koyanagi--Harada (VKH) syndrome is a multisystem disease which can often result in blindness. It is featured by a bilateral granulomatous panuveitis and concomitant extraocular symptoms, including vitiligo, alopecia, poliosis, impaired auditory sense and central nervous system lesions [@pone.0098373-Yang1], [@pone.0098373-Murthy1]. An autoimmune reaction against melanocytes which may be triggered by infection or other factors, is thought to be involved in the pathogenesis of VKH disease [@pone.0098373-Yang1]. We have shown that CD4 T cells and several inflammatory cytokines play an important role in the progress of the disorder [@pone.0098373-Chi2]. Although the definite pathogenesis of the two diseases has not been determined, recent studies have shown an important role for an immunogenetic predisposition to both diseases. Various studies have demonstrated that several genes such as human leukocyte antigen (HLA)-B51, IL-23R, DHCR7, and TLR-2 are associated with BD [@pone.0098373-Verity1], [@pone.0098373-Jiang1], [@pone.0098373-Fang1], [@pone.0098373-Fang2]. Furthermore, HLA-DR4, IL-17, STAT4 have been identified as predisposing factors for VKH syndrome [@pone.0098373-Zhao1], [@pone.0098373-Shu1], [@pone.0098373-Hu1].

Interleukins are types of cytokine signaling molecules in the immune system and play important roles in regulating the activities of lymphocytes that are responsible for immunity. Interleukin-12B (IL-12B) encodes the key subunit IL-12p40 which is the common component of IL-12 and IL-23. The bioactive subunit is generated mainly by activated macrophages and dendritic cells in response to pathogenic or inflammatory factors [@pone.0098373-Trinchieri1], [@pone.0098373-Trinchieri2]. IL-12p40 deficiency leads to decreased migration of dendritic cells and diminished ability to activate naive T cells [@pone.0098373-Khader1]. It also has considerable roles in the function of the Th1 and Th17 cells [@pone.0098373-Johnston1], [@pone.0098373-Lim1], the two significant kinds of T-helper subsets involved in many important immunological processes. Morahan et al [@pone.0098373-Morahan1] have revealed that differences in the degree of IL-12p40 production may have significant impact on T cell reactivity which plays an essential role in immune-related diseases. Recent studies indicated that a genetic aberration of the IL-12B gene is associated with several autoimmune diseases such as ankylosing spondylitis (AS) and psoriasis [@pone.0098373-Wong1], [@pone.0098373-Cargill1]. Interleukin-12-receptor-β1 (IL-12Rβ1) is a receptor chain which is shared by IL-12 and IL-23. IL-12Rβ1 is critical for the function and development of memory CD4 T cells [@pone.0098373-Cleary1]. The IL-12Rβ1-dependent pathway is essential for the differentiation and proliferation of human Th17 cell subsets [@pone.0098373-deBeaucoudrey1]. IL-12Rβ1 knockout mice have been shown to be resistant to Experimental Autoimmune Encephalomyelitis (EAE) [@pone.0098373-Zhang1]. Mutations in the IL-12Rβ1 gene have been shown to be associated with immune disorders [@pone.0098373-vandeVosse1]. IL-12Rβ2 is the other subunit of the IL-12 receptors. IL-12Rβ2 is essential in Th1 development and is also associated with IL-17 expression [@pone.0098373-Szabo1], [@pone.0098373-Toh1]. Furthermore, IL-12Rβ2 deficiency can lead to a diminished recruitment of activated T cells and an abnormal expression of inflammatory cytokines [@pone.0098373-Fauconnier1].

Given the fact that these related genes (IL-12B, IL-12Rβ1 and IL-12Rβ2) play an important role in Th1 and Th17 related immune responses, we wanted to verify the potential evidence of an association of polymorphisms in these genes with uveitis. We chose BD and VKH as representative examples of uveitis in view of the fact that a sufficiently large sample size could be obtained. Eight SNPs of the three genes (IL-12B, IL-12Rβ1 and IL-12Rβ2) were selected for our study, whereby the choice was dictated by previous studies showing a definite association with other autoimmune diseases.

Materials and Methods {#s2}
=====================

Study Population {#s2a}
----------------

This case control study was composed of two phases. In the first phase we tested 400 BD patients, 400 VKH syndrome patients and 600 healthy controls. In the second stage, which was separate from the first one, another set of 406 BD patients, 420 VKH cases and another 1000 healthy subjects were included. All the individuals had visited the uveitis clinic at the First Affiliated Hospital of Chongqing Medical University, Chongqing, China and Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou, China, between April 2005 and December 2013. The healthy controls were geographically and ethnically matched with the patients. All the subjects involved in this study were Han Chinese. The diagnostic criteria for BD and VKH syndrome were precisely followed as described by the International Study Group for BD [@pone.0098373-International1] and First International Workshop for VKH [@pone.0098373-Read1]. The clinical features of the BD and VKH disease patients included in our study are presented in [table 1](#pone-0098373-t001){ref-type="table"}.

10.1371/journal.pone.0098373.t001

###### Clinical features of the investigated BD and VKH syndrome patients.

![](pone.0098373.t001){#pone-0098373-t001-1}

  Extraocular findings        Total      \%
  ------------------------ ----------- ------
  **Patients with BD**         806     
  Mean age ± SD             33.7±8.9   
  Male                         699      86.7
  Female                       107      13.3
  Uveitis                      806      100
  Oral ulcer                   806      100
  Genital ulcer                460      57.1
  Skin lesions                 610      75.7
  Arthritis                    119      14.8
  Positive pathergy test       153      19.0
  **Patients with VKH**        820     
  Mean age ± SD             39.0±13.8  
  Male                         438      53.4
  Female                       382      46.6
  Uveitis                      820      100
  Headache                     325      39.6
  Tinnitus                     249      30.4
  Vitiligo                     152      18.5
  Poliosis                     303      37.0
  **Normal controls**          820     
  Mean age ± SD             39.7±10.7  
  Male                         869      54.3
  Female                       731      45.7

BD, Behcet\'s disease; VKH, Vogt--Koyanagi--Harada syndrome.

The ethics committee of the First Affiliated Hospital of Chongqing Medical University approved the study protocol (Permit Number: 2009-201008) and all procedures followed the tenets of the Declaration of Helsinki. All the participants provided their written informed consent to participate in this study. We recorded all the participant consents in the book which kept the whole consents in it. The study was registered in the Chinese Clinical Trial Registry. The registration number is ChiCTR-CCC-12002184.

SNP selection and genotyping {#s2b}
----------------------------

According to previous reported associations of the three IL-12 related genes (IL-12B, IL-12Rβ1 and IL-12Rβ2) polymorphisms with autoimmune disorders, five SNPs of IL-12B (rs3212227, rs6887695, rs3212217, rs10045431, rs2082412), one SNP of IL-12Rβ1 (rs438421) and two SNPs for IL-12Rβ2 (rs3790565, rs3790567) were chosen for our study to detect the potential relevance of these genes with our two uveitis entities. The selected SNPs and a sketch of the gene structure are shown in [Figure 1](#pone-0098373-g001){ref-type="fig"}. Genomic DNA of the subjects was extracted with the QIA amp DNA Blood Mini Kit (Qiagen, Valencia, CA). After this, the extracted DNA samples were stored at -20°C.

![The sketch of gene structure of the selected SNPs.](pone.0098373.g001){#pone-0098373-g001}

The appropriate primers used to amplify the corresponding target DNA sequence by PCR and corresponding restriction enzymes are shown in [Table 2](#pone-0098373-t002){ref-type="table"}. Five percent agarose gels were used to separate the digestion products and stained with GoldView TM (SBS Genetech, Beijing, China). To ensure the validity of the method for our study, 20% of all samples were stochastically selected for direct sequencing by Sangon Biotech Company (Shanghai, China).

10.1371/journal.pone.0098373.t002

###### Primers and restriction enzymes used for restricted fragment length polymorphisms analysis of the IL12B, IL-12Rβ1 and IL-12Rβ2 genes.

![](pone.0098373.t002){#pone-0098373-t002-2}

  Gene        SNP number               Primers               Restriction enzyme
  ---------- ------------ --------------------------------- --------------------
  IL-12B      rs3212227     5′GACACAACGGAATAGACCCAAAAAG3′           TaqI
                            5′GGCAACTTGAGAGCTGGAAAATCT 3′   
              rs6887695     5′GAGAGAAGCAGTGTAGTGTAGTGAT3′           BclI
                              5′GAACAGAGAGGGGAAGCAAC3′      
              rs10045431   5′CAGGGTAGTGGGTATTGTCCTAAGTAT3′         HinfI
                           5′GGGTAGTGGGTATTGTCCTAAGTATGC3   
              rs3212217    5′ TAAAGTACATAGCAAGGTCCGCCTCG3′          XhoI
                             5′ AGCACCCATGGTCTGGAGGAAA3′    
              rs2082412    5′ TCTCCTCTCCAGAGTGTTCCAGTAA3′           SduI
                           5′CGAGTGAAATTGTACAAATGCAAAGTG3′  
  IL-12Rβ1     rs438421       5′CACCACCGACATGCACTTGAA3′             StyI
                            5′ AGGGATGACTGTCTCCATTCCAC3′    
  IL-12Rβ2    rs3790565    5′ GGTCTATTGTAAATCCCTAGTGAGG 3′          TaqI
                            5′GGGAGATAGAGTTGAATATTGCATC3′   
              rs3790567     5′GAAAAGCCCTCCTCTCTACCTTAA3′           AflII
                            5′CTTGTGGTCTTCACATTTGTCTTG3′    

Statistical analysis {#s2c}
--------------------

The χ2 test was applied for the evaluation of the Hardy-Weinberg equilibrium. Direct counting was used to assess the genotype frequencies. The χ2 test using SPSS (version 13.0) was used for the comparison of genotype and allele frequencies between patients and healthy controls. Bonferroni correction was carried out for the correction of multiple comparisons by multiplying p values with the number of analyses performed. A statistical significant difference was considered when the p~c~\<0.05.

Results {#s3}
=======

Clinical features of BD/VKH {#s3a}
---------------------------

The clinical characteristics of the enrolled BD patients and VKH cases are shown in [Table 1](#pone-0098373-t001){ref-type="table"}. BD and VKH disease usually appear in the young and middle aged population. The features for BD comprise relapsing ulcerations in the oral cavity and genital region, skin lesions and arthritis. Extraocular symptoms of VKH syndrome include vitiligo, alopecia, poliosis, impaired auditory sense and central nervous system lesions. Details of the enrolled controls are also shown in [Table 1](#pone-0098373-t001){ref-type="table"}.

Associations of the IL-12B gene polymorphisms with susceptibility to BD {#s3b}
-----------------------------------------------------------------------

In the first part of this case-control study, eight SNPs of the three IL-12 related genes (IL-12B, IL-12Rβ1 and IL-12Rβ2) were genotyped successfully in 400 BD patients and 600 healthy controls. The obtained data of healthy subjects were in agreement with the Hardy-Weinberg equilibrium. Frequencies of the rs3212227/IL-12B genotype CC and C allele were significantly higher in the BD patients (p~c~ = 0.009, OR 1.8, 95% CI 1.3 to 2.4; p~c~ = 0.024, OR 1.3, 95% CI 1.1 to 1.6, respectively) compared with the normal controls. To confirm the result, a second set of patients was used to replicate the associated SNP rs3212227/IL-12B using another 406 BD samples and another set of 1000 healthy controls. In the second stage, the frequencies of the rs3212227/IL-12B genotype CC and C allele were also significantly higher in BD cases (p~c~ = 3.5×10^−4^, OR = 1.8, 95% CI 1.4 to 2.4; p~c~ = 0.002, OR = 1.4, 95% CI 1.2 to 1.6, respectively) than that observed in the control group. Subsequently, we analyzed the combined data of the two studies, which showed a consistent association of the CC genotype and C allele of rs3212227/IL-12B with BD (p~c~ ~comb~ = 6.3×10^−7^, OR = 1.8, 95% CI 1.5 to 2.2; p~c~ ~comb~ = 2.0×10^−5^, OR = 1.3, 95% CI 1.2 to 1.5, respectively). There was no significant association between BD and the other tested SNPs (four of IL-12B, one of IL-12Rβ1 and two of IL-12Rβ2 ([Table 3](#pone-0098373-t003){ref-type="table"}). Since several organs may be affected by BD, a further study was undertaken to explore the association of these SNPs with the clinical manifestations in the BD cases. No associations between tested gene polymorphisms with the separate features of BD could be detected (data not shown).

10.1371/journal.pone.0098373.t003

###### Frequencies of genotypes and alleles of IL12B, IL-12Rβ1 and IL-12Rβ2 polymorphisms in patients with BD and controls.
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  SNPs              Stage      Genotype      Case        Control       P value     P~c~ value         OR(95%CI)
  ------------- ------------- ---------- ------------ ------------- ------------- ------------- ---------------------
                    First        A A      114(0.285)   199(0.332)       0.119          NS        0.803(0.610--1.058)
                                 A C      188(0.470)   308(0.513)       0.179          NS        0.841(0.653--1.083)
                                 C C      98(0.245)     93(0.155)    3.90×10^−4^      0.009      1.769(1.288--2.430)
                                  A       416(0.520)   706(0.588)       0.003         0.024      0.758(0.633--0.908)
                                  C       384(0.480)   494(0.412)       0.003         0.024      1.319(1.102--1.580)
  rs3212227      Replication     A A      110(0.271)   323(0.323)       0.055          NS        0.779(0.603--1.006)
  (IL-12B)                       A C      190(0.468)   516(0.516)       0.103          NS        0.825(0.655--1.040)
                                 C C      106(0.261)   161(0.161)    1.45×10^−5^   3.48×10^−4^   1.841(1.394--2.432)
                                  A       410(0.505)   1162(0.581)   2.31×10^−4^      0.002      0.736(0.624--0.866)
                                  C       402(0.495)   838(0.419)    2.31×10^−4^      0.002      1.360(1.154--1.601)
                  Combined       A A      224(0.278)   522(0.326)       0.016          NS        0.795(0.660--0.958)
                                 A C      378(0.469)   824(0.515)       0.033          NS        0.832(0.702--0.985)
                                 C C      204(0.253)   254(0.159)    2.63×10^−8^   6.31×10^−7^   1.796(1.459--2.211)
                                  A       826(0.512)   1868(0.584)   2.53×10^−6^   2.02×10^−5^   0.749(0.664--0.845)
                                  C       786(0.488)   1332(0.416)   2.53×10^−6^   2.02×10^−5^   1.334(1.183--1.505)
  rs6887695         First        C C      62(0.155)     87(0.145)       0.664          NS        1.082(0.760--1.540)
  (IL-12B)                       C G      199(0.497)   303(0.505)       0.540          NS        0.924(0.719--1.188)
                                 G G      139(0.348)   210(0.350)       0.935          NS        0.989(0.758--1.290)
                                  C       323(0.404)   477(0.398)       0.780          NS        1.026(0.855--1.232)
                                  G       477(0.596)   723(0.602)       0.780          NS        0.974(0.812--1.169)
  rs10045431        First        A C      54(0.135)     88(0.147)       0.605          NS        0.908(0.630--1.308)
  (IL-12B)                       C C      346(0.865)   512(0.853)       0.605          NS        1.101(0.764--1.587)
                                  A       54(0.068)     88(0.073)       0.619          NS        0.915(0.644--1.300)
                                  C       746(0.932)   1112(0.927)      0.619          NS        1.093(0.769--1.553)
  rs3212217         First        C C      83(0.207)    101(0.168)       0.117          NS        1.294(0.937--1.786)
  (IL-12B)                       C G      214(0.535)   317(0.528)       0.836          NS        1.027(0.797--1.324)
                                 G G      103(0.258)   182(0.304)       0.095          NS        0.785(0.591--1.043)
                                  C       380(0.475)   519(0.432)       0.061          NS        1.187(0.992--1.421)
                                  G       420(0.525)   681(0.568)       0.061          NS        0.842(0.704--1.008)
  rs2082412         First        A A      72(0.180)    104(0.173)       0.786          NS        1.047(0.752--1.458)
  (IL-12B)                       A G      210(0.525)   311(0.518)       0.836          NS        1.027(0.797--1.323)
                                 G G      118(0.295)   185(0.309)       0.653          NS        0.939(0.712--1.237)
                                  A       354(0.443)   519(0.432)       0.659          NS        1.041(0.870--1.247)
                                  G       446(0.557)   681(0.568)       0.659          NS        0.960(0.802--1.150)
  rs438421          First        A A      35(0.087)     66(0.110)       0.247          NS        0.776(0.504--1.194)
  (IL-12 Rβ1)                    A G      178(0.445)   281(0.468)       0.468          NS        0.910(0.706--1.174)
                                 G G      187(0.468)   253(0.422)       0.153          NS        1.204(0.933--1.553)
                                  A       248(0.310)   413(0.344)       0.112          NS        0.856(0.707--1.037)
                                  G       552(0.690)   787(0.656)       0.112          NS        1.168(0.965--1.414)
  rs3790565         First        C C      17(0.043)     19(0.032)       0.368          NS        1.357(0.697--2.644)
  (IL-12 Rβ2)                    C T      146(0.365)   194(0.323)       0.173          NS        1.203(0.922--1.569)
                                 T T      237(0.592)   387(0.645)       0.093          NS        0.800(0.617--1.038)
                                  C       180(0.225)   232(0.193)       0.086          NS        1.211(0.973--1.508)
                                  T       620(0.775)   968(0.807)       0.086          NS        0.826(0.663--1.028)
  rs3790567         First        A A      26(0.065)     25(0.042)       0.100          NS        1.599(0.909--2.811)
  (IL-12 Rβ2)                    A G      162(0.405)   232(0.387)       0.561          NS        1.080(0.834--1.398)
                                 G G      212(0.530)   343(0.571)       0.194          NS        0.845(0.655--1.090)
                                  A       214(0.268)   282(0.235)       0.099          NS        1.189(0.968--1.460)
                                  G       586(0.733)   918(0.765)       0.099          NS        0.841(0.685--1.033)

SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NS, no significant different; freq, frequency; p~c~, p Bonferroni correction.

IL-12B gene confers susceptibility to VKH syndrome {#s3c}
--------------------------------------------------

In the first study we included 400 VKH patients and 600 normal controls. The samples of patients and controls were genotyped for the eight SNPs mentioned above. We found that the C allele frequency of rs3212227/IL-12B was significantly increased in VKH patients (p~c~ = 0.012, OR 1.3, 95% CI 1.1 to 1.6). Based on this result, we performed a confirmatory study with another set of 420 VKH cases and 1000 healthy individuals. Consistent with the result in the first study, the C allele frequency of rs3212227/IL-12B was markedly increased in VKH patients as compared to normal subjects (p~c~ = 0.046, OR 1.3, 95% CI 1.1 to 1.6). Subsequently, we analyzed the combined data of all the cases and controls. The data confirmed the C allele frequency of rs3212227/IL-12B as the risk factor for VKH (p~c~ = 2.5×10^−5^, OR 1.3, 95% CI 1.2 to 1.5). No statistically significant association was found between VKH and the other seven SNPs tested ([Table 4](#pone-0098373-t004){ref-type="table"}). In addition, no associations could be detected between the separate VKH disease characteristics and the investigated SNPs (data not shown).

10.1371/journal.pone.0098373.t004

###### Frequencies of genotypes and alleles of IL12B, IL-12Rβ1 and IL-12Rβ2 polymorphisms in patients with VKH patients and controls.
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  SNPs              Stage      Genotype      Case        Control       P value     P~c~ value         OR(95%CI)
  ------------- ------------- ---------- ------------ ------------- ------------- ------------- ---------------------
                    First        A A      94(0.235)    199(0.332)       0.001         0.024      0.619(0.465--0.825)
                                 A C      225(0.562)   308(0.513)       0.127          NS        1.219(0.945--1.572)
                                 C C      81(0.203)     93(0.155)       0.052          NS        1.384(0.996--1.924)
                                  A       413(0.516)   706(0.588)      0.0015         0.012      0.747(0.624--0.894)
                                  C       387(0.484)   494(0.412)      0.0015         0.012      1.339(1.118--1.603)
  rs3212227      Replication     A A      98(0.233)    323(0.323)    7.34×10^−4^      0.018      0.638(0.491--0.829)
  (IL-12B)                       A C      233(0.555)   516(0.516)       0.182          NS        1.169(0.930--1.469)
                                 C C      89(0.212)    161(0.161)       0.022          NS        1.401(1.050--1.870)
                                  A       429(0.511)   1162(0.581)   5.73×10^−4^      0.046      0.753(0.640--0.885)
                                  C       411(0.489)   838(0.419)    5.73×10^−4^      0.046      1.328(1.130--1.562)
                  Combined       A A      192(0.234)   522(0.326)    2.57×10^−6^   6.17×10^−5^   0.631(0.521--0.765)
                                 A C      458(0.559)   824(0.515)       0.042          NS        1.191(1.006--1.411)
                                 C C      170(0.207)   254(0.159)       0.003          NS        1.386(1.117--1.719)
                                  A       842(0.513)   1868(0.584)   3.08×10^−6^   2.46×10^−5^   0.752(0.668--0.848)
                                  C       798(0.487)   1332(0.416)   3.08×10^−6^   2.46×10^−5^   1.329(1.179--1.498)
  rs6887695         First        C C      61(0.152)     87(0.145)       0.744          NS        1.061(0.744--1.513)
  (IL-12B)                       C G      216(0.541)   303(0.505)       0.278          NS        1.151(0.893--1.483)
                                 G G      123(0.307)   210(0.350)       0.162          NS        0.825(0.629--1.081)
                                  C       338(0.422)   477(0.398)       0.265          NS        1.109(0.925--1.330)
                                  G       462(0.578)   723(0.602)       0.265          NS        0.902(0.752--1.082)
  rs10045431        First        A C      56(0.140)     88(0.147)       0.769          NS        0.947(0.660--1.360)
  (IL-12B)                       C C      344(0.860)   512(0.853)       0.769          NS        1.056(0.735--1.516)
                                  A       56(0.070)     88(0.073)       0.778          NS        0.951(0.672--1.347)
                                  C       744(0.930)   1112(0.927)      0.778          NS        1.051(0.743--1.489)
  rs3212217         First        C C      77(0.193)    101(0.168)       0.328          NS        1.178(0.849--1.635)
  (IL-12B)                       C G      213(0.532)   317(0.528)       0.897          NS        1.017(0.789--1.310)
                                 G G      110(0.275)   182(0.304)       0.334          NS        0.871(0.658--1.153)
                                  C       367(0.459)   519(0.432)       0.247          NS        1.112(0.929--1.331)
                                  G       433(0.541)   681(0.568)       0.247          NS        0.899(0.751--1.076)
  rs2082412         First        A A      90(0.225)    104(0.173)       0.100          NS        1.306(0.950--1.797)
  (IL-12B)                       A G      196(0.490)   311(0.518)       0.570          NS        0.929(0.721--1.197)
                                 G G      114(0.285)   185(0.309)       0.430          NS        0.894(0.677--1.180)
                                  A       376(0.470)   519(0.432)       0.152          NS        1.140(0.953--1.365)
                                  G       424(0.530)   681(0.568)       0.152          NS        0.877(0.733--1.050)
  rs438421          First        A A      38(0.095)     66(0.110)       0.447          NS        0.849(0.558--1.294)
  (IL-12 Rβ1)                    A G      189(0.472)   281(0.468)       0.897          NS        1.017(0.789--1.310)
                                 G G      173(0.433)   253(0.422)       0.734          NS        1.045(0.809--1.350)
                                  A       265(0.331)   413(0.344)       0.550          NS        0.944(0.781--1.141)
                                  G       535(0.669)   787(0.656)       0.550          NS        1.059(0.877--1.280)
  rs3790565         First        C C      12(0.030)     19(0.032)       0.882          NS        0.946(0.454--1.970)
  (IL-12Rβ2)                     C T      128(0.320)   194(0.323)       0.912          NS        0.985(0.751--1.291)
                                 T T      260(0.650)   387(0.645)       0.871          NS        1.022(0.784--1.332)
                                  C       152(0.190)   232(0.193)       0.853          NS        0.979(0.780--1.229)
                                  T       648(0.810)   968(0.807)       0.853          NS        1.022(0.814--1.283)
  rs3790567         First        A A      24(0.060)     25(0.042)       0.188          NS        1.468(0.826--2.609)
  (IL-12Rβ2)                     A G      157(0.393)   232(0.387)       0.853          NS        1.025(0.791--1.328)
                                 G G      219(0.547)   343(0.571)       0.450          NS        0.907(0.703--1.170)
                                  A       205(0.256)   282(0.235)       0.278          NS        1.122(0.912--1.380)
                                  G       595(0.744)   918(0.765)       0.278          NS        0.892(0.725--1.097)

SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NS, no significant different; freq, frequency; p~c~, p Bonferroni correction.

We analyzed the data of five SNPs of IL-12B for LD (Linkage Disequilibrium), and found that there was no linkage between these loci ([Figure 2](#pone-0098373-g002){ref-type="fig"}). In addition, we performed a comparison between BD and VKH, and between patients (BD and VKH) and controls. The data were in agreement with the present results both in BD and VKH group ([Table 5](#pone-0098373-t005){ref-type="table"} and [Table 6](#pone-0098373-t006){ref-type="table"}, respectively).

![Pair-wise linkage disequilibrium values of IL-12B SNPs in a Chinese Han population.\
Linkage Disequilibrium (LD) block was estimated for IL-12B gene locus using our data. The pair-wise D\' Values are shown in blocks.](pone.0098373.g002){#pone-0098373-g002}
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###### Comparison of frequencies of genotypes and alleles of IL12B, IL-12Rβ1 and IL-12Rβ2 polymorphisms between BD and VKH cases.

![](pone.0098373.t005){#pone-0098373-t005-5}

  SNPs              Stage      Genotype    BD Case      VKH Case      P value     P~c~ value        BD vs VKH
  ------------- ------------- ---------- ------------ ------------ ------------- ------------ ---------------------
                    First        A A      114(0.285)   94(0.235)       0.107          NS       1.298(0.945--1.782)
                                 A C      188(0.470)   225(0.562)      0.009          NS       0.690(0.522--0.911)
                                 C C      98(0.245)    81(0.203)       0.149          NS       1.278(0.915--1.784)
                                  A       416(0.520)   413(0.516)      0.881          NS       1.015(0.834--1.235)
                                  C       384(0.480)   387(0.484)      0.881          NS       0.985(0.810--1.199)
  rs3212227      Replication     A A      110(0.271)   98(0.233)       0.213          NS       1.221(0.891--1.673)
  (IL-12B)                       A C      190(0.468)   233(0.555)      0.013          NS       0.706(0.537--0.928)
                                 C C      106(0.261)   89(0.212)       0.096          NS       1.314(0.952--1.814)
                                  A       410(0.505)   429(0.511)      0.814          NS       0.977(0.806--1.185)
                                  C       402(0.495)   411(0.489)      0.814          NS       1.023(0.844--1.241)
                  Combined       A A      224(0.278)   192(0.234)      0.043          NS       1.259(1.007--1.574)
                                 A C      378(0.469)   458(0.559)   3.03×10^−4^     0.007      0.698(0.574--0.849)
                                 C C      204(0.253)   170(0.207)      0.028          NS       1.296(1.028--1.634)
                                  A       826(0.512)   842(0.513)      0.954          NS       0.996(0.868--1.143)
                                  C       786(0.488)   798(0.487)      0.954          NS       1.004(0.875--1.152)
  rs6887695         First        C C      62(0.155)    61(0.152)       0.922          NS       1.019(0.694--1.497)
  (IL-12B)                       C G      199(0.497)   216(0.541)      0.229          NS       0.843(0.639--1.113)
                                 G G      139(0.348)   123(0.307)      0.228          NS       1.199(0.892--1.612)
                                  C       323(0.404)   338(0.422)      0.446          NS       0.926(0.759--1.129)
                                  G       477(0.596)   462(0.578)      0.446          NS       1.080(0.885--1.318)
  rs10045431        First        A C      54(0.135)    56(0.140)       0.837          NS       0.959(0.641--1.434)
  (IL-12B)                       C C      346(0.865)   344(0.860)      0.837          NS       1.043(0.697--1.560)
                                  A       54(0.068)    56(0.070)       0.843          NS       0.962(0.653--1.417)
                                  C       746(0.932)   744(0.930)      0.843          NS       1.040(0.706--1.532)
  rs3212217         First        C C      83(0.207)    77(0.193)       0.596          NS       1.098(0.777--1.553)
  (IL-12B)                       C G      214(0.535)   213(0.532)      0.943          NS       1.010(0.765--1.334)
                                 G G      103(0.258)   110(0.275)      0.576          NS       0.914(0.668--1.251)
                                  C       380(0.475)   367(0.459)      0.515          NS       1.067(0.877--1.299)
                                  G       420(0.525)   433(0.541)      0.515          NS       0.937(0.770--1.140)
  rs2082412         First        A A      72(0.180)    90(0.225)       0.113          NS       0.756(0.535--1.069)
  (IL-12B)                       A G      210(0.525)   196(0.490)      0.322          NS       1.150(0.872--1.518)
                                 G G      118(0.295)   114(0.285)      0.755          NS       1.050(0.773--1.425)
                                  A       354(0.443)   376(0.470)      0.269          NS       0.895(0.735--1.090)
                                  G       446(0.557)   424(0.530)      0.269          NS       1.117(0.918--1.360)
  rs438421          First        A A      35(0.087)    38(0.095)       0.713          NS       0.913(0.564--1.479)
  (IL-12 Rβ1)                    A G      178(0.445)   189(0.472)      0.435          NS       0.895(0.678--1.182)
                                 G G      187(0.468)   173(0.433)      0.320          NS       1.152(0.872--1.522)
                                  A       248(0.310)   265(0.331)      0.362          NS       0.907(0.735--1.119)
                                  G       552(0.690)   535(0.669)      0.362          NS       1.103(0.894--1.360)
  rs3790565         First        C C      17(0.043)    12(0.030)       0.344          NS       1.435(0.676--3.045)
  (IL-12 Rβ2)                    C T      146(0.365)   128(0.320)      0.180          NS       1.221(0.912--1.637)
                                 T T      237(0.592)   260(0.650)      0.094          NS       0.783(0.588--1.042)
                                  C       180(0.225)   152(0.190)      0.084          NS       1.238(0.971--1.577)
                                  T       620(0.775)   648(0.810)      0.084          NS       0.808(0.634--1.030)
  rs3790567         First        A A      26(0.065)    24(0.060)       0.770          NS       1.089(0.614--1.932)
  (IL-12 Rβ2)                    A G      162(0.405)   157(0.393)      0.718          NS       1.054(0.794--1.398)
                                 G G      212(0.530)   219(0.547)      0.620          NS       0.932(0.706--1.231)
                                  A       214(0.268)   205(0.256)      0.609          NS       1.060(0.848--1.325)
                                  G       586(0.733)   595(0.744)      0.609          NS       0.943(0.755--1.179)

SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NS, no significant different; freq, frequency; p~c~, p Bonferroni correction.

10.1371/journal.pone.0098373.t006

###### Comparison of frequencies of genotypes and alleles of IL12B, IL-12Rβ1 and IL-12Rβ2 polymorphisms between cases (BD + VKH) and controls.

![](pone.0098373.t006){#pone-0098373-t006-6}

  SNPs              Stage      Genotype     BD+VKH        Control       P value     P~c~ value         OR(95%CI)
  ------------- ------------- ---------- ------------- ------------- ------------- ------------- ---------------------
                    First        A A      208(0.260)    199(0.332)       0.003          NS        0.708(0.561--0.893)
                                 A C      413(0.516)    308(0.513)       0.914          NS        1.012(0.819--1.250)
                                 C C      179(0.224)     93(0.155)       0.001         0.024      1.571(1.192--2.072)
                                  A       829(0.518)    706(0.588)    2.21×10^−4^      0.002      0.752(0.647--0.875)
                                  C       771(0.482)    494(0.412)    2.21×10^−4^      0.002      1.329(1.143--1.546)
  rs3212227      Replication     A A      208(0.252)    323(0.323)    8.57×10^−4^      0.021      0.705(0.574--0.866)
  (IL-12B)                       A C      423(0.512)    516(0.516)       0.868          NS        0.985(0.819--1.184)
                                 C C      195(0.236)    161(0.161)    5.56×10^−5^      0.001      1.610(1.276--2.033)
                                  A       839(0.508)    1162(0.581)   9.89×10^−6^   7.91×10^−5^   0.744(0.653--0.849)
                                  C       813(0.492)    838(0.419)    9.89×10^−6^   7.91×10^−5^   1.344(1.179--1.532)
                  Combined       A A      416(0.256)    522(0.326)    1.07×10^−5^   2.57×10^−4^   0.710(0.609--0.827)
                                 A C      836(0.514)    824(0.515)       0.961          NS        0.997(0.868--1.144)
                                 C C      374(0.230)    254(0.159)    3.20×10^−7^   7.68×10^−6^   1.583(1.326--1.889)
                                  A       1668(0.513)   1868(0.584)   1.09×10^−8^   8.72×10^−8^   0.751(0.681--0.828)
                                  C       1584(0.487)   1332(0.416)   1.09×10^−8^   8.72×10^−8^   1.332(1.207--1.469)
  rs6887695         First        C C      123(0.154)     87(0.145)       0.650          NS        1.071(0.796--1.443)
  (IL-12B)                       C G      415(0.519)    303(0.505)       0.610          NS        1.057(0.855--1.306)
                                 G G      262(0.327)    210(0.350)       0.378          NS        0.904(0.723--1.131)
                                  C       661(0.413)    477(0.398)       0.405          NS        1.067(0.916--1.243)
                                  G       939(0.587)    723(0.602)       0.405          NS        0.937(0.805--1.092)
  rs10045431        First        A C      110(0.138)     88(0.147)       0.626          NS        0.928(0.685--1.255)
  (IL-12B)                       C C      690(0.863)    512(0.853)       0.626          NS        1.078(0.797--1.459)
                                  A       110(0.069)     88(0.073)       0.640          NS        0.933(0.697--1.248)
                                  C       1490(0.931)   1112(0.927)      0.640          NS        1.072(0.801--1.434)
  rs3212217         First        C C      160(0.200)    101(0.168)       0.132          NS        1.235(0.938--1.626)
  (IL-12B)                       C G      427(0.534)    317(0.528)       0.841          NS        1.022(0.827--1.263)
                                 G G      213(0.266)    182(0.304)       0.127          NS        0.833(0.659--1.053)
                                  C       747(0.467)    519(0.432)       0.071          NS        1.149(0.988--1.336)
                                  G       853(0.533)    681(0.568)       0.071          NS        0.870(0.749--1.012)
  rs2082412         First        A A      162(0.202)    104(0.173)       0.169          NS        1.211(0.922--1.591)
  (IL-12B)                       A G      406(0.508)    311(0.518)       0.688          NS        0.958(0.775--1.183)
                                 G G      232(0.290)    185(0.309)       0.458          NS        0.916(0.727--1.154)
                                  A       730(0.456)    519(0.432)       0.211          NS        1.101(0.947--1.280)
                                  G       870(0.544)    681(0.568)       0.211          NS        0.908(0.781--1.056)
  rs438421          First        A A       73(0.091)     66(0.110)       0.246          NS        0.812(0.572--1.154)
  (IL-12 Rβ1)                    A G      367(0.459)    281(0.468)       0.722          NS        0.962(0.778--1.190)
                                 G G      360(0.450)    253(0.422)       0.290          NS        1.122(0.906--1.389)
                                  A       513(0.321)    413(0.344)       0.190          NS        0.899(0.767--1.054)
                                  G       1087(0.679)   787(0.656)       0.190          NS        1.112(0.949--1.303)
  rs3790565         First        C C       29(0.036)     19(0.032)       0.641          NS        1.150(0.639--2.072)
  (IL-12 Rβ2)                    C T      274(0.343)    194(0.323)       0.452          NS        1.090(0.871--1.365)
                                 T T      497(0.621)    387(0.645)       0.362          NS        0.903(0.725--1.125)
                                  C       332(0.208)    232(0.193)       0.355          NS        1.092(0.906--1.318)
                                  T       1268(0.792)   968(0.807)       0.355          NS        0.915(0.759--1.104)
  rs3790567         First        A A       50(0.063)     25(0.042)       0.087          NS        1.533(0.937--2.508)
  (IL-12 Rβ2)                    A G      319(0.399)    232(0.387)       0.647          NS        1.052(0.847--1.307)
                                 G G      431(0.538)    343(0.571)       0.220          NS        0.875(0.707--1.083)
                                  A       419(0.262)    282(0.235)       0.104          NS        1.155(0.971--1.374)
                                  G       1181(0.738)   918(0.765)       0.104          NS        0.866(0.728--1.030)

SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NS, no significant different; freq, frequency; p~c~, p Bonferroni correction.

Discussion {#s4}
==========

This study shows that IL-12B gene polymorphisms are associated with two uveitis entities known as BD and VKH syndrome. The C allele of rs3212227/IL-12B confers risk to both BD and VKH. On the other hand, we failed to find a significant association between a set of seven other tested SNPs which belong to a group of three IL-12 related genes (IL-12B, IL-12Rβ1 and IL-12Rβ2) and either BD or VKH syndrome.

The data confirm previous associations between IL-12B gene polymorphisms and several autoimmune diseases such as ankylosing spondylitis and psoriasis [@pone.0098373-Wong1], [@pone.0098373-Cargill1]. There is abundant evidence that immune response pathways in which IL-12 p40 (encoded by IL-12B) is involved may play an important role in the pathogenesis of uveitis. Previous reports have demonstrated that both Th1 and Th17 responses are augmented in Behcet\'s patients [@pone.0098373-Guenane1], [@pone.0098373-Na1]. The expression of IL-12p40 was shown to be higher in serum of BD patients [@pone.0098373-Chi1]. Previous studies have also suggested that differences in the degree of IL-12p40 production may have an important impact on T cells reactivity [@pone.0098373-Morahan1]. As mentioned above, IL-12B polymorphisms have been reported to be associated with several immune disorders [@pone.0098373-Wong1], [@pone.0098373-Cargill1]. In these studies an association was found for the SNP rs3212227 with AS and psoriasis.

Our data are not in agreement with preceding studies in BD from other ethnic populations. A small study with Turkish BD patients reported that the AC genotype and A allele frequency of rs3212227 were significantly higher in BD patients (BD cases: control = 80∶105, p = 0.015) [@pone.0098373-Alayli1]. Another small Japanese study did not find an association between rs3212227 and BD (BD cases: control = 55∶65) [@pone.0098373-Yanagihori1]. The difference between these studies and ours is that they were performed in BD patients with a different ethnic background and that the sample size was much lower.

Both the CC genotype and C allele of rs3212227/IL-12B were significantly increased in BD, whereas in VKH only the frequency of the C allele was significantly increased compared to the healthy controls. Statistical analysis did not show a significant association for the CC genotype as observed in the BD patients. Our findings add to the growing list of immune response gene mutations that are involved in the pathogenesis of both VKH and BD. Immune response genes such as HLA-DR4, IL-17 and STAT4 have been reported to be associated with VKH [@pone.0098373-Zhao1], [@pone.0098373-Shu1], [@pone.0098373-Hu1]. In BD gene mutations have been shown to be involved in disease susceptibility including human leukocyte antigen (HLA)-B51, IL-23R, DHCR7, and TLR-2 [@pone.0098373-Verity1], [@pone.0098373-Jiang1], [@pone.0098373-Fang1], [@pone.0098373-Fang2].

Regarding the different genotypes of rs3212227 that confer susceptibility to various diseases in different ethnic groups, it has been reported that the A allele is a risk allele [@pone.0098373-Kaarvatn1], [@pone.0098373-Oka1]. On the other hand, there are other studies which describe the C allele as the risk allele [@pone.0098373-Wong1], [@pone.0098373-Tao1]. Differences between these results may due to the distinct nature of diseases in patients with a different ethnic background.

The effect of rs3212227 genotypes on the production of IL-12p40 by cultured cells is controversial. It has been reported that the rs3212227 CC/AC genotypes are associated with significantly decreased serum IL-12p40 levels [@pone.0098373-Wang1]. However, there are other studies showing that different genotypes of rs3212227 do not mediate functional changes in IL-12p40 production [@pone.0098373-Ongecha1], [@pone.0098373-Seegers1].

The exact mode of action of IL-12B rs3212227 gene polymorphisms and disease therefore remains unclear. Further functional studies are needed to clarify this issue.

We did not find significant associations with IL-12Rβ1 or IL-12Rβ2 and the two uveitis entities we studied. These two important receptors for IL-12, which have been reported to be associated with several autoimmune diseases [@pone.0098373-Namkung1], [@pone.0098373-Hirschfield1], play important roles in the immune response. It is possible that other SNPs in these three IL-12 related genes may play a role in uveitis. Further studies should be performed to address this issue.

There are a number of limitations in this study. We detected an association of rs3212227/IL-12B with BD and VKH patients in a Chinese Han population and our data cannot yet be extrapolated to other ethnic groups. BD and VKH syndrome are accompanied by various extraocular symptoms. Our patients were recruited by a department of ophthalmology and it is possible that our patients represent a subpopulation of these diseases. Analysis of patients from other medical departments should be carried out to rule out patient subgroup bias. Our data were confined to uveitis patients with BD and VKH and further studies should be carried out to investigate whether IL-12B is also involved in the pathogenesis of other uveitis entities. As mentioned above there might be differences in disease association in other ethnic patient populations and confirmation in other ethnic groups is necessary to solve this limitation.

In conclusion, this study shows an association between rs3212227/IL-12B polymorphisms with BD and VKH syndrome in a Chinese Han population, which supports a role for IL-12B in the development of intraocular inflammation in both BD and VKH syndrome.
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